Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients

T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic breast cancer patients who had progressed to taxanes and trastuzumab. We have...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Sci Rep
Prif Awduron: Hardy-Werbin, Max, Quiroga, Vanesa, Cirauqui, Beatriz, Romeo, Margarita, Felip, Eudald, Teruel, Iris, Garcia, Juan Jose, Erasun, Carlos, España, Sofia, Cucurull, Marc, Montprade, Elisabeth, Pardo, Juan Carlos, Carballo, Dania, Velarde, Jose Maria, Margeli, Mireia
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726763/
https://ncbi.nlm.nih.gov/pubmed/31484985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-49251-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg